DNA-PKcs promotes cardiac ischemia reperfusion injury through mitigating BI-1-governed mitochondrial homeostasis

Hao Zhou1,2, Sam Toan3, Pingjun Zhu4

  • 1Department of Cardiology, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, 100853, China. zhouhao@plagh.org.

Insights

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) promotes cardiac injury by degrading Bax inhibitor-1 (BI-1). Ablating DNA-PKcs protects the heart from ischemia reperfusion injury by stabilizing BI-1.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Biology
  • Molecular Cardiology

Background:

  • DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is known to induce apoptosis and suppress tumor growth.
  • Its role in cardiovascular diseases, particularly cardiac ischemia reperfusion (IR) injury, is not well understood.

Purpose of the Study:

  • To investigate the role of DNA-PKcs in cardiac IR injury and associated mitochondrial damage.
  • To elucidate the molecular mechanisms underlying DNA-PKcs-mediated cardioprotection or cardiotoxicity.

Main Methods:

  • Utilized cardiomyocyte-specific DNA-PKcs knockout (DNA-PKcsCKO) mice subjected to IR injury.
  • Assessed myocardial function, infarct size, cardiomyocyte apoptosis, oxidative stress, mitochondrial dynamics, and mitophagy.
  • Investigated the interaction between DNA-PKcs and Bax inhibitor-1 (BI-1) using molecular assays.

Main Results:

  • IR challenge activated DNA-PKcs in murine hearts and cardiomyocytes via post-transcriptional phosphorylation.
  • DNA-PKcsCKO mice exhibited protection against IR-induced cardiac dysfunction, infarct expansion, and cardiomyocyte death.
  • DNA-PKcs ablation reduced oxidative stress, mPTP opening, mitochondrial fission, and mitophagy failure, partly by stabilizing BI-1 and inhibiting its degradation.
  • Concurrent knockout of BI-1 abolished the cardioprotective effects of DNA-PKcs deletion.

Conclusions:

  • DNA-PKcs acts as a novel causative factor in cardiac IR injury by promoting mitochondrial damage through the suppression of BI-1.
  • Targeting DNA-PKcs or preserving BI-1 function may represent a therapeutic strategy for mitigating cardiac IR injury.